207 Claudin18.2-targeting CAB-T cells have superior safety over traditional CAR-T, while maintaining potent in vivo anti-tumor efficacy

BackgroundWe have developed a proprietary T cell-based anti-CD3 T cell engager delivery platform (named CAB-T), which includes two elements: a chimeric CD3e/signaling component and a CD3-based bispecific T cell engager (TCE). We have previously shown the efficacy vs. safety advantages of the CAB-T s...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal for immunotherapy of cancer 2022-11, Vol.10 (Suppl 2), p.A221-A221
Hauptverfasser:	Chai, Jitian, Huang, Weifeng, Peng, Shaogang, Zhang, Zhenqing, Yao, Yan, Chuan-Chu Chou, Tsun, Andy, Li, Zhiyuan
Format:	Artikel
Sprache:	eng
Schlagworte:	Immunotherapy Lymphocytes Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!